Pacira Biosciences

Traded on the St. Petersburg Stock Exchange
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on the development, commercialization and manufacture of new pharmaceutical products, based on its proprietary DepoFoam® drug delivery technology, for use in hospitals and ambulatory surgery centers. Pacira is a leading provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving patient outcomes.
Pacira Biosciences stock price chart
vol.
change
P/E adj.
Net profit (adj.)
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Pacira Biosciences balance sheet

Report period2018 2019 2020 2021 2022 2023
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Pacira Biosciences cash flows

Report period2018 2019 2020 2021 2022 2023
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
Adjusted Earnings
EBITDA
Adjusted EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS
Adjusted EPS

Pacira Biosciences multipliers

Report period2018 2019 2020 2021 2022 2023
P/E
P/E adj.
E/P
E adj./P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
Net Debt/EBITDA adj.
EV/EBITDA
EV/EBITDA adj.

Pacira Biosciences profitability

Report period2018 2019 2020 2021 2022 2023
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Pacira Biosciences assets
Pacira Biosciences cash flows

Pacira Biosciences shares

TickerNameTypeNominal valueISINPrice
PCRX:USPacira Biosciences, Inc.Common share-US6951271005$28.67
Pacira Biosciences news
04.05.2022
Net income of Pacira Biosciences under GAAP for the 3 months of 2022 was $6.828 million, down 34.1% from $10.369 million in the previous year. Revenue increased 32.7% to $157.991 million from $119.027 million a year earlier.
Source: {source} pictogram investor.pacira.com
Pictogram next
24.02.2022
Pacira Biosciences' GAAP net income for 2021 was $41.98 million, down 3.5 times from $145.523 million in the previous year. Revenue increased 26% to $541.533 million from $429.647 million a year earlier.
Source: {source} pictogram investor.pacira.com
Pictogram next
19.11.2021
Pacira BioSciences bought Flexion Therapeutics for $8.5 per share. The company will pay up to $8 more per share, contingent on reaching Zilretta's sales targets and approval of two candidates in Phase 1 clinical trials. Zilretta was approved by the FDA in 2017 as a non-opioid pain reliever for osteoarthritis of the knee and is Flexion's primary drug of choic...
Source: {source} pictogram investor.pacira.com
Pictogram next
03.11.2021
Pacira Biosciences' GAAP net income for 9M 2021 was $47.11 million, down 2.8 times from $131.008 million in the previous year. Revenue increased 28% to $382.339 million from $298.673 million a year earlier.
Source: {source} pictogram investor.pacira.com
Pictogram next
All Pacira Biosciences news
General information
Company namePacira Biosciences
Tags#pharmacy
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals / Pharmaceuticals
Business address5 SYLVAN WAY SUITE 300 PARSIPPANY NJ 07054 973-254-3560
Mailing address5 SYLVAN WAY SUITE 300 PARSIPPANY NJ 07054
Websitewww.pacira.com
Information disclosurewww.sec.gov